1.
Cell Stem Cell
; 30(10): 1287-1289, 2023 10 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37802033
RESUMO
In this issue of Cell Stem Cell, Bershteyn et al.1 developed a human interneuron cell therapy that reduced spontaneous seizure activity in a mouse model of mesial temporal lobe epilepsy (MTLE). The data presented here support an ongoing phase 1/2 clinical trial for the treatment of pharmaco-resistant epilepsy in patients.